Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.
ER-100 has moved partial epigenetic reprogramming from animal models into a first-in-human trial in glaucoma and NAION. Its development program will test not only whether retinal ganglion cell function can be restored, but also how FDA may evaluate a new therapeutic concept built around rejuvenating injured neurons rather than replacing them.
Human cartilage grafts span distinct FDA regulatory pathways depending on tissue source, processing, intended use, and cellular characteristics. Allogeneic structural grafts, surgical autografts, and cultured chondrocyte products therefore present materially different regulatory strategies.
The approval of Simtriyo expands the ADHD treatment landscape and illustrates how regulatory differentiation increasingly depends on mechanism, formulation design, pediatric evidence, abuse-potential controls, and lifecycle planning.
An assessment of FDA approvals since 2020 show that novel clinician-reported outcomes can support primary, secondary, and labeling claims, but only when the endpoint is interpretable in its specific context of use. Five applications illustrate how instrument design, rater standardization, estimands, and fallback evidence shape the regulatory outcome.
Induced pluripotent stem cell-derived blood stem cells could expand the sources available for hematopoietic transplantation and create a platform for genetic correction. Recent preclinical studies strengthen the rationale for durable and molecularly youthful grafts, while leaving human efficacy, safety, and manufacturability unresolved.
Recent FDA approvals show expanding scientific and regulatory flexibility for novel antimicrobials. The harder precedent remains commercial: narrow labels, stewardship-constrained use, and fragile launch economics continue to threaten otherwise valuable products.
FDA's RMAT approval record reveals several repeatable evidentiary models, from paired-lesion randomization to natural history controls and response-based accelerated approval. The pathway is most valuable when enhanced FDA interaction is used to resolve product-specific uncertainty rather than to avoid it.
Individualized mRNA vaccines have progressed from demonstrations of immune activation to randomized efficacy testing in resected cancer. Intismeran autogene leads the field, while autogene cevumeran and several early-stage platforms are testing whether the model can extend across tumors and development settings.
Solid-tumor CAR-T has crossed the regulatory threshold, but the clinical evidence remains uneven. One randomized program shows a real but modest survival gain, while several early programs produce striking responses in small, selected cohorts without yet establishing durable population-level benefit.
Adquey adds another nonsteroidal topical option for mild-to-moderate atopic dermatitis. Its approval is especially notable for how FDA evaluated two positive Japanese pivotal trials, supportive multinational evidence, and an incomplete U.S. Phase 3 study.
The first FDA approval confirms that a heterobifunctional degrader can complete the clinical and regulatory pathway. The broader pipeline and its growing record of discontinuations show why target degradation alone is not enough.
Single-trial approvals were already a substantial part of FDA practice before the 2026 policy debate. The revised draft guidance points toward wider use of one-trial programs, but not toward a lower evidentiary burden in every setting.
The lessons from failed Alzheimer's programs become clearer when read against the therapies that secured FDA approval. The resulting record shows that regulatory success depends on the complete alignment of mechanism, disease stage, exposure, biomarker strategy, clinical outcomes, safety, and approval pathway.